Bio-Rad launches new SARS-CoV-2 panels

By LabPulse.com staff writers

September 30, 2021 -- Bio-Rad Laboratories has launched Bio-Plex immunoglobulin A (IgA) and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The panels are for research use only.

Bio-Rad's Bio-Plex Pro Human IgA SARS-CoV-2 S1/S2/N/RBD 4-Plex Panel and the Bio-Plex Pro Human IgM SARS-CoV-2 S1/S2/N/RBD 4-Plex Panel join Bio-Rad's existing Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel to complete the set of three separate qualitative multiplex I immunoassays that detect IgA, IgM, and IgG antibodies against four SARS-CoV-2 antigens, the company said.

The panels can assist researchers in developing vaccines, as well as help public health researchers who perform seroprevalence studies based on serology specimens to identify individuals who may have been exposed to SARS-CoV-2, the company said.

Bio-Rad partners with Seegene
Bio-Rad Laboratories announced a partnership with South Korean molecular diagnostics company Seegene to develop and commercialize new diagnostic products...
BioRad teams with Biodesix on COVID-19 total antibody test
Bio-Rad Laboratories and lung cancer diagnostics firm Biodesix have joined forces to launch a serology test for detecting COVID-19 antibodies.
Bio-Rad COVID-19 test cleared in U.S.
Bio-Rad Laboratories has garnered emergency use authorization from the U.S. Food and Drug Administration for its droplet digital polymerase chain reaction...
Bio-Rad launches COVID-19 antibody test kit
Bio-Rad Laboratories has begun shipping its SARS-CoV-2 Total Ab blood-based immunoassay kit.
Bio-Rad debuts guide to improve access to COVID-19 tests
Bio-Rad Laboratories has launched a standard for SARS-CoV-2 to help labs validate assays and speed up access to testing for COVID-19 novel coronavirus...

Copyright © 2021 LabPulse.com

Last Updated ls 9/30/2021 5:15:01 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current